Takeaways from this week in optometry: August 10-August 14

Mohammad Rafieetary, OD, FAAO, FORS, DipABO, ABCMO, details his AAOpt 2026 presentation "Photobiomodulation in Age-Related Macular Degeneration: Evidence, Mechanisms, and Clinical Integration."

Aflibercept 8 mg cut RVO injections by up to 3 over 64 weeks in QUASAR, while a pair of additional posters show Amsler gaps in AMD and BRAO-linked stroke risk.

A young woman had years of headaches, dizziness, and intolerance of her phone despite normal routine eye examinations. A modest prism gave her immediate relief.

Phil Rainey, OD, MPH, FAAO, states that the recent parameter expansion of Johnson & Johnson's Acuvue Oasys Max 1-Day and Oasys 1-Day has been a game changer for his practice.

A pair of cases from Academy 2026 show scleral lens refits for severe keratoconus, one addressing focal corneal edema and one fitting around glaucoma tube shunts.

Neda Gioia, OD, CNS, FMCP, FOWNS, CFMP, details a lack of research exploring the intersection of hormones and ocular health in women and what health care as a whole should investigate next.

Shane Kannarr, OD, overviews results from a phase 4, multicenter, prospective, open-label trial that evaluated the impact of concomitant use of PFHO during contact lens wear.

To kick off Perimenopause and Menopause Awareness Month, Meredith Bishop, OD, MS, FAAO, gives an overview of her poster "Perceptions of Linking Presbyopia with Perimenopause: A Survey of US Female Eye Care Professionals."